Yujue Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yujue Wang has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Juan Tao
Department of Dermatology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST) Wuhan China
2 shared publications Aayoung Hong
Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
1 shared publicationAlain P. Algazi
Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94143, USA
1 shared publicationAlan J. Tackett
Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
1 shared publication- Alexis M. Jones
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
1 shared publication Antoni Ribas
1 shared publication
Latest Publications
- 29 July 2025
- Published by Elsevier in Biomaterials
- Vol. 325, 123577
Microliter-scale ethanol confinement array with biofluidic triggered release for dual-enhanced precision chemotherapy
- 29 July 2025
- Published by Elsevier in Biomaterials
- Vol. 325, 123577
Microliter-scale ethanol confinement array with biofluidic triggered release for dual-enhanced precision chemotherapy
- Open Access
- 10 April 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (11) , 2828-2838.e10
Tolerogenic Monocyte-Derived Langerhans Cells Promote Melanoma Progression and Immunotherapy Resistance through Aryl Hydrocarbon Receptor–Cyclooxygenase-2 Activation
- 10 April 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (11) , 2828-2838.e10
Open AccessTolerogenic Monocyte-Derived Langerhans Cells Promote Melanoma Progression and Immunotherapy Resistance through Aryl Hydrocarbon Receptor–Cyclooxygenase-2 Activation
- Open Access
- 24 August 2023
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-22
Hyperoside protects against oxidative stress-mediated photoreceptor degeneration: therapeutic potentials for photoreceptor degenerative diseases
Background: Photoreceptor degeneration underpinned by oxidative stress-mediated mitochondrial dysfunction and cell death leads to progressive and irreversible vision impairment. Drug treatments that protect against photoreceptor degeneration are currently available in the clinical settings. It has been shown that hyperoside, a flavonol glycoside, protects against neuronal loss in part by suppressing oxidative stress and maintaining the functional integrity of mitochondria. However, whether hyperoside protects against photoreceptor degeneration remains unknown. Methods: To address the pharmacological potentials of hyperoside against oxidative stress-mediated photoreceptor degeneration on molecular, cellular, structural and functional levels, multiple in vitro and in vivo methodologies were employed in the current study, including live-cell imaging, optical coherence tomography, electroretinography, histological/immunohistochemical examinations, transmission electron microscopy, RNA-sequencing and real-time qPCR. Results: The in vitro results demonstrate that hyperoside suppresses oxidative stress-mediated photoreceptor cell death in part by mitigating mitochondrial dysfunction. The in vivo results reveal that hyperoside protects against photooxidative stress-induced photoreceptor morphological, functional and ultrastructural degeneration. Meanwhile, hyperoside treatment offsets the deleterious impact of photooxidative stress on multiple molecular pathways implicated in the pathogenesis of photoreceptor degeneration. Lastly, hyperoside attenuates photoreceptor degeneration-associated microglial inflammatory activation and reactive Müller cell gliosis. Conclusions: All things considered, the present study demonstrates for the first time that hyperoside attenuates oxidative stress-induced photoreceptor mitochondrial dysfunction and cell death. The photoreceptor-intrinsic protective effects of hyperoside are corroborated by hyperoside-conferred protection against photooxidative stress-mediated photoreceptor degeneration and perturbation in retinal homeostasis, warranting further evaluation of hyperoside as a photoreceptor protective agent for the treatment of related photoreceptor degenerative diseases.
- 24 August 2023
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-22
Open AccessHyperoside protects against oxidative stress-mediated photoreceptor degeneration: therapeutic potentials for photoreceptor degenerative diseases
Background: Photoreceptor degeneration underpinned by oxidative stress-mediated mitochondrial dysfunction and cell death leads to progressive and irreversible vision impairment. Drug treatments that protect against photoreceptor degeneration are currently available in the clinical settings. It has been shown that hyperoside, a flavonol glycoside, protects against neuronal loss in part by suppressing oxidative stress and maintaining the functional integrity of mitochondria. However, whether hyperoside protects against photoreceptor degeneration remains unknown. Methods: To address the pharmacological potentials of hyperoside against oxidative stress-mediated photoreceptor degeneration on molecular, cellular, structural and functional levels, multiple in vitro and in vivo methodologies were employed in the current study, including live-cell imaging, optical coherence tomography, electroretinography, histological/immunohistochemical examinations, transmission electron microscopy, RNA-sequencing and real-time qPCR. Results: The in vitro results demonstrate that hyperoside suppresses oxidative stress-mediated photoreceptor cell death in part by mitigating mitochondrial dysfunction. The in vivo results reveal that hyperoside protects against photooxidative stress-induced photoreceptor morphological, functional and ultrastructural degeneration. Meanwhile, hyperoside treatment offsets the deleterious impact of photooxidative stress on multiple molecular pathways implicated in the pathogenesis of photoreceptor degeneration. Lastly, hyperoside attenuates photoreceptor degeneration-associated microglial inflammatory activation and reactive Müller cell gliosis. Conclusions: All things considered, the present study demonstrates for the first time that hyperoside attenuates oxidative stress-induced photoreceptor mitochondrial dysfunction and cell death. The photoreceptor-intrinsic protective effects of hyperoside are corroborated by hyperoside-conferred protection against photooxidative stress-mediated photoreceptor degeneration and perturbation in retinal homeostasis, warranting further evaluation of hyperoside as a photoreceptor protective agent for the treatment of related photoreceptor degenerative diseases.
- Open Access
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S362
Abstract 1460: Identifying GABA de novo synthesis route in cancer cells
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S362
Open AccessAbstract 1460: Identifying GABA de novo synthesis route in cancer cells
- Open Access
- 1 October 2021
- Published by Elsevier in Cancer Cell
- Vol. 39 (10) , 1375-1387.e6
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy
- 1 October 2021
- Published by Elsevier in Cancer Cell
- Vol. 39 (10) , 1375-1387.e6
Open AccessAnti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy
- Open Access
- 1 December 2020
- Published by JLE in European Journal Of Dermatology
- Vol. 30 (6) , 738-740
Safety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China
- 1 December 2020
- Published by JLE in European Journal Of Dermatology
- Vol. 30 (6) , 738-740
Open AccessSafety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China